Medicare Enrolled
Dr. Baijia Jiang, M.D.
Hematology & Oncology · Anaheim, CA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Jiang from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Jiang?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Jiang
Dr. Baijia Jiang is a hematology & oncology specialist in Anaheim, CA, with 10 years of NPI registration. Based on federal Medicare data, Dr. Jiang performed 3,875 Medicare services across 1,189 unique beneficiaries.
Between the years covered by Open Payments, Dr. Jiang received a total of $10,511 from 48 pharmaceutical and/or device companies across 394 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Jiang is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 10 years in practice
▲ Top 35% volume in CA
$10,511 industry payments
Medicare Practice Summary
Medicare Utilization ↗3,875
Medicare services
Top 35% in CA for hematology & oncology
1,189
Unique beneficiaries
$46
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~388 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
1,177 | $8 | $18 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
1,086 | $8 | $30 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
697 | $104 | $195 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
473 | $71 | $150 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
112 | $98 | $203 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
92 | $150 | $250 |
| New patient office visit, complex (60-74 min) | 79 | $168 | $371 |
| Enhanced Oncology Model monthly payment This code represents the monthly enhanced oncology services payment under the Enhancing Oncology Model. It covers the administrative payment for enhanced services provided to eligible patients. |
64 | $71 | $100 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
51 | $143 | $392 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
44 | $134 | $295 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$10,511
Total received (2018-2024)
Avg $1,502/year across 7 years
Top 31% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
48
Companies
394
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$9,049 (86.1%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$1,367 (13.0%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$95 (0.9%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$3,630
2023
$4,841
2022
$1,576
2021
$157
2020
$95
2019
$102
2018
$111
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$441
ABBVIE INC.
$326
E.R. Squibb & Sons, L.L.C.
$275
Incyte Corporation
$222
Astellas Pharma US Inc
$182
Daiichi Sankyo Inc.
$179
Merck Sharp & Dohme LLC
$167
Celgene Corporation
$163
Janssen Biotech, Inc.
$154
Alexion Pharmaceuticals, Inc.
$153
PFIZER INC.
$142
EMD Serono, Inc.
$130
Eisai Inc.
$125
Novartis Pharmaceuticals Corporation
$122
PharmaEssentia USA Corporation
$116
Gilead Sciences, Inc.
$101
SOBI, INC
$83
Genentech USA, Inc.
$54
GENZYME CORPORATION
$46
Coherus Biosciences Inc.
$45
Blueprint Medicines Corporation
$37
Mirati Therapeutics, Inc.
$37
Regeneron Healthcare Solutions, Inc.
$36
ARRAY BIOPHARMA INC
$33
TAIHO ONCOLOGY, INC.
$30
Blue Earth Diagnostics Limited
$28
Boehringer Ingelheim Pharmaceuticals, Inc.
$28
GlaxoSmithKline, LLC.
$28
Myriad Genetic Laboratories, Inc.
$27
Takeda Pharmaceuticals U.S.A., Inc.
$25
Lilly USA, LLC
$22
Agios Pharmaceuticals, Inc.
$21
Fresenius Kabi USA, LLC
$21
Cumberland Pharmaceuticals, Inc.
$16
Alnylam Pharmaceuticals Inc.
$15
Top 3 companies account for 28.7% of 2024 payments
All-time payments by company (2018-2024) ›
PFIZER INC.
$1,757
AstraZeneca Pharmaceuticals LP
$1,159
Incyte Corporation
$702
E.R. Squibb & Sons, L.L.C.
$555
Merck Sharp & Dohme LLC
$462
ABBVIE INC.
$448
Amgen Inc.
$445
Novartis Pharmaceuticals Corporation
$388
Celgene Corporation
$386
Seagen Inc.
$372
Astellas Pharma US Inc
$345
Daiichi Sankyo Inc.
$270
GENZYME CORPORATION
$263
Alexion Pharmaceuticals, Inc.
$243
Janssen Biotech, Inc.
$242
Gilead Sciences, Inc.
$218
EMD Serono, Inc.
$202
PharmaEssentia USA Corporation
$188
Eisai Inc.
$154
Pharmacyclics LLC, An AbbVie Company
$148
Progenics Pharmaceuticals, Inc.
$125
Stemline Therapeutics Inc.
$120
Mirati Therapeutics, Inc.
$117
Exelixis Inc.
$101
Genentech USA, Inc.
$99
Lilly USA, LLC
$99
SOBI, INC
$83
GlaxoSmithKline, LLC.
$79
Pharmacyclics LLC, an AbbVie Company
$78
Karyopharm Therapeutics Inc.
$65
Takeda Pharmaceuticals U.S.A., Inc.
$65
Myriad Genetic Laboratories, Inc.
$54
TAIHO ONCOLOGY, INC.
$52
Coherus Biosciences Inc.
$45
MorphoSys, US Inc.
$43
Blueprint Medicines Corporation
$37
Regeneron Healthcare Solutions, Inc.
$36
ARRAY BIOPHARMA INC
$33
ADC Therapeutics America, Inc.
$32
EISAI INC.
$31
Blue Earth Diagnostics Limited
$28
Boehringer Ingelheim Pharmaceuticals, Inc.
$28
Deciphera Pharmaceuticals Inc.
$24
Agios Pharmaceuticals, Inc.
$21
Fresenius Kabi USA, LLC
$21
Taiho Oncology, Inc.
$16
Cumberland Pharmaceuticals, Inc.
$16
Alnylam Pharmaceuticals Inc.
$15
Top 3 companies account for 34.4% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · ALUNBRIG · AYVAKIT · BAVENCIO · BESREMI · Bavencio · Blincyto · CABOMETYX · CALQUENCE · CARVYKTI · Cabometyx · DARZALEX · DOPTELET · ELAHERE · ELIQUIS · ELITEK · ELREXFIO · ENHERTU · EPKINLY · EVENITY · Enhertu · Fabhalta · GILOTRIF · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · JAKAFI · JEMPERLI · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LONSURF · LOQTORZI · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · MEKINIST · MONJUVI · MYRISK · NINLARO · Nplate · ONPATTRO · OPDIVO · OPDUALAG · Orserdu · PEMAZYRE · PLUVICTO · POSLUMA · PROMACTA · PYLARIFY · PYRUKYND · Padcev · Pomalyst · QINLOCK · REBLOZYL · RYBREVANT · SANCUSO · SARCLISA · Stimufend · TECVAYLI · TEPMETKO · TUKYSA · Tecentriq · ULTOMIRIS · Udenyca · VENCLEXTA · VERZENIO · Venclexta · Vyloy · XALKORI · XPOVIO · XTANDI · Xospata · Xtandi · ZEJULA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (86%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
328
Per 100K population
10.4
County median income
$113,702
Nearest hospital
AHMC ANAHEIM REGIONAL MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Jiang is a clinical cardiology specialist, with moderate Medicare volume, with low-engagement industry engagement.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Jiang experienced with blood draw (venipuncture)?
Based on Medicare claims data, Dr. Jiang performed 1,177 blood draw (venipuncture) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Jiang receive payments from pharmaceutical companies?
Yes. Dr. Jiang received a total of $10,511 from 48 companies across 394 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Jiang's costs compare to other hematology & oncology specialists in Anaheim?
Dr. Jiang's average Medicare payment per service is $46. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Jiang) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Anaheim
Browse hematology & oncology specialists in Anaheim ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in CA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in CA
Which CA hematology & oncology specialists receive the most from drug and device companies.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Incyte Corporation Payments to Doctors
See all physicians who received payments from Incyte Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology